GlaxoSmithKline Pharmaceuticals (GSK) has announced the launch of its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, reinforcing its commitment to addressing the unmet need for gynaecological cancers in the country.

Jemperli is India’s first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer.  Zejula is a once-daily oral PARP inhibitor approved as monotherapy for first-line maintenance treatment for patients with advanced or relapsed epithelial ovarian cancer who are in complete or partial response to platinum-based chemotherapy, regardless of biomarker status.

Bhushan Akshikar, Managing Director, GSK India, said: “The launch of Jemperli and Zejula marks a pivotal moment for GSK in India, as we foray into oncology with a strong focus on innovation-led, high-impact therapies. These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women’s cancer care. With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India.”

Dr. Shalini Menon, EVP – Medical Affairs, GSK India, highlighted that gynaecological cancers represent a growing public health challenge in India, especially among women above the age of 50, and those with obesity and metabolic syndrome.

“Jemperli introduces immunotherapy into the treatment paradigm for advanced or recurrent endometrial cancer, offering a targeted option for patients with dMMR tumours. Zejula expands access to a convenient, first-line maintenance therapy in advanced ovarian cancer,” she stated.

These innovative therapies are supported by robust global clinical evidence and approvals from more than 40 countries, including the US, UK, and EU. In India, GSK is also participating in ongoing oncology clinical trials aimed at extending the indication of dostarlimab to other cancers, including non-small cell lung, head and neck, and colorectal.  

Gynaecological cancers rank among the most common cancers affecting women in India, and their incidence continues to rise. Endometrial and ovarian cancers are among the three most prevalent gynaecological cancers in the country, with projections indicating a sharp increase by 2045—78 percent for endometrial cancer and 69 percent for ovarian cancer.

To empower patients to access these newly launched therapies, GSK is introducing ‘Phoenix’, a Patient Support Program.